BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

264 related articles for article (PubMed ID: 27832086)

  • 1. Serum Calprotectin Discriminates Subclinical Disease Activity from Ultrasound-Defined Remission in Patients with Rheumatoid Arthritis in Clinical Remission.
    Hurnakova J; Hulejova H; Zavada J; Komarc M; Hanova P; Klein M; Mann H; Sleglova O; Olejarova M; Forejtova S; Ruzickova O; Vencovsky J; Pavelka K; Senolt L
    PLoS One; 2016; 11(11):e0165498. PubMed ID: 27832086
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Relationship between serum calprotectin (S100A8/9) and clinical, laboratory and ultrasound parameters of disease activity in rheumatoid arthritis: A large cohort study.
    Hurnakova J; Hulejova H; Zavada J; Hanova P; Komarc M; Mann H; Klein M; Sleglova O; Olejarova M; Forejtova S; Ruzickova O; Vencovsky J; Pavelka K; Senolt L
    PLoS One; 2017; 12(8):e0183420. PubMed ID: 28832684
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serum calprotectin (S100A8/9): an independent predictor of ultrasound synovitis in patients with rheumatoid arthritis.
    Hurnakova J; Zavada J; Hanova P; Hulejova H; Klein M; Mann H; Sleglova O; Olejarova M; Forejtova S; Ruzickova O; Komarc M; Vencovsky J; Pavelka K; Senolt L
    Arthritis Res Ther; 2015 Sep; 17(1):252. PubMed ID: 26373925
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Serum calprotectin may reflect inflammatory activity in patients with active rheumatoid arthritis despite normal to low C-reactive protein.
    Hurnakova J; Hulejova H; Zavada J; Komarc M; Cerezo LA; Mann H; Vencovsky J; Pavelka K; Senolt L
    Clin Rheumatol; 2018 Aug; 37(8):2055-2062. PubMed ID: 29656372
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Serum Calprotectin Versus Acute-Phase Reactants in the Discrimination of Inflammatory Disease Activity in Rheumatoid Arthritis Patients Receiving Tumor Necrosis Factor Inhibitors.
    Inciarte-Mundo J; Victoria Hernández M; Ruiz-Esquide V; Raquel Cabrera-Villalba S; Ramirez J; Cuervo A; Pascal M; Yagüe J; Cañete JD; Sanmarti R
    Arthritis Care Res (Hoboken); 2016 Jul; 68(7):899-906. PubMed ID: 26841119
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Calprotectin and TNF trough serum levels identify power Doppler ultrasound synovitis in rheumatoid arthritis and psoriatic arthritis patients in remission or with low disease activity.
    Inciarte-Mundo J; Ramirez J; Hernández MV; Ruiz-Esquide V; Cuervo A; Cabrera-Villalba SR; Pascal M; Yagüe J; Cañete JD; Sanmarti R
    Arthritis Res Ther; 2016 Jul; 18(1):160. PubMed ID: 27391315
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Calprotectin more accurately discriminates the disease status of rheumatoid arthritis patients receiving tocilizumab than acute phase reactants.
    Inciarte-Mundo J; Ruiz-Esquide V; Hernández MV; Cañete JD; Cabrera-Villalba SR; Ramirez J; Yagüe J; Sanmarti R
    Rheumatology (Oxford); 2015 Dec; 54(12):2239-43. PubMed ID: 26242859
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Using a DAS28-CRP-steered treat-to-target strategy does not eliminate subclinical inflammation as assessed by ultrasonography in rheumatoid arthritis patients in longstanding clinical remission.
    Terslev L; Brahe CH; Østergaard M; Fana V; Ammitzbøll-Danielsen M; Møller T; Krabbe S; Hetland ML; Døhn UM
    Arthritis Res Ther; 2021 Feb; 23(1):48. PubMed ID: 33522948
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Calprotectin as a marker of inflammation in patients with early rheumatoid arthritis.
    Jonsson MK; Sundlisæter NP; Nordal HH; Hammer HB; Aga AB; Olsen IC; Brokstad KA; van der Heijde D; Kvien TK; Fevang BS; Lillegraven S; Haavardsholm EA
    Ann Rheum Dis; 2017 Dec; 76(12):2031-2037. PubMed ID: 28814431
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Calprotectin strongly and independently predicts relapse in rheumatoid arthritis and polyarticular psoriatic arthritis patients treated with tumor necrosis factor inhibitors: a 1-year prospective cohort study.
    Inciarte-Mundo J; Ramirez J; Hernández MV; Ruiz-Esquide V; Cuervo A; Cabrera-Villalba SR; Pascal M; Yagüe J; Cañete JD; Sanmarti R
    Arthritis Res Ther; 2018 Dec; 20(1):275. PubMed ID: 30545393
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Calprotectin (a major leucocyte protein) is strongly and independently correlated with joint inflammation and damage in rheumatoid arthritis.
    Hammer HB; Odegard S; Fagerhol MK; Landewé R; van der Heijde D; Uhlig T; Mowinckel P; Kvien TK
    Ann Rheum Dis; 2007 Aug; 66(8):1093-7. PubMed ID: 17234650
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical and sonographic biomarkers of structural damage progression in RA patients in clinical remission: A prospective study with 12 months follow-up.
    Ramírez J; Narváez JA; Ruiz-Esquide V; Hernández-Gañán J; Cuervo A; Inciarte-Mundo J; Hernández MV; Sampayo-Cordero M; Pablos JL; Sanmartí R; Cañete JD
    Semin Arthritis Rheum; 2017 Dec; 47(3):303-309. PubMed ID: 28549731
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of Serum Calprotectin Level and Disease Activity in Patients with Rheumatoid Arthritis.
    Aghdashi MA; Seyedmardani S; Ghasemi S; Khodamoradi Z
    Curr Rheumatol Rev; 2019; 15(4):316-320. PubMed ID: 30666913
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Calprotectin levels in rheumatoid arthritis and their correlation with disease activity: a meta-analysis.
    Bae SC; Lee YH
    Postgrad Med; 2017 Jun; 129(5):531-537. PubMed ID: 28425837
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Calprotectin (S100A8/A9) and S100A12 are associated with measures of disease activity in a longitudinal study of patients with rheumatoid arthritis treated with infliximab.
    Nordal HH; Brun JG; Hordvik M; Eidsheim M; Jonsson R; Halse AK
    Scand J Rheumatol; 2016 Jul; 45(4):274-81. PubMed ID: 26767827
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Differing local and systemic inflammatory burden in polyarticular psoriatic arthritis and rheumatoid arthritis patients on anti-TNF treatment in clinical remission.
    Ramírez J; Inciarte-Mundo J; Cuervo A; Ruiz-Esquide V; Hernández MV; Sanmartí R; Cañete JD
    Clin Exp Rheumatol; 2017; 35(1):74-79. PubMed ID: 27749227
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Musculoskeletal ultrasound as a biomarker of remission - results from a one-year prospective study in patients with rheumatoid arthritis.
    Sapundzhieva T; Karalilova R; Batalov A
    Med Ultrason; 2018 Dec; 20(4):453-460. PubMed ID: 30534652
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ultrasound-defined remission for good functional status in rheumatoid arthritis.
    Ozer PK; Sahin O; Ozer Z; Cengiz AK; Durmaz Y; Kaptanoglu E
    Indian J Med Res; 2017 Aug; 146(2):230-236. PubMed ID: 29265024
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Calprotectin (a major leucocyte protein) is associated with the levels of anti-CCP and rheumatoid factor in a longitudinal study of patients with very early rheumatoid arthritis.
    Hammer HB; Haavardsholm EA; Kvien TK
    Scand J Rheumatol; 2008; 37(3):179-82. PubMed ID: 18465451
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Calprotectin (a major S100 leucocyte protein) predicts 10-year radiographic progression in patients with rheumatoid arthritis.
    Hammer HB; Ødegård S; Syversen SW; Landewé R; van der Heijde D; Uhlig T; Mowinckel P; Kvien TK
    Ann Rheum Dis; 2010 Jan; 69(1):150-4. PubMed ID: 19095696
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.